Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Int J Rheum Dis ; 26(8): 1529-1539, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37317623

RESUMEN

AIM: The Chinese anti-rheumatic herbal remedy Tripterygium wilfordii Hook F (TWHF) has been widely shown to be effective in treating lupus nephritis (LN), but the therapeutic targets and mechanisms of action are still unclear. In this study, we aimed to combine mRNA expression profile analysis and network pharmacology analysis to screen the pathogenic genes and pathways involved in LN and to explore the potential targets of TWHF in the treatment of LN. METHODS: The mRNA expression profiles of LN patients were used to screen differentially expressed genes (DEGs) and to predict associated pathogenic pathways and networks via the Ingenuity Pathway Analysis database. Through molecular docking, we predicted the mechanism by which TWHF interacts with candidate targets. RESULTS: A total of 351 DEGs were screened from the glomeruli of LN patients and were mainly concentrated in the role of pattern recognition receptors in the recognition of bacteria and viruses and interferon signaling pathways. A total of 130 DEGs were screened from the tubulointerstitium of LN patients, which were concentrated in the interferon signaling pathway. TWHF might be effective in treating LN by hydrogen bonding to regulate the functions of 24 DEGs (including HMOX1, ALB, and CASP1), which are mainly concentrated in the B-cell signaling pathway. CONCLUSION: The mRNA expression profile of renal tissue from LN patients revealed a large number of DEGs. TWHF has been shown to interact with the DEGs (including HMOX1, ALB and CASP1) through hydrogen bonding to treat LN.


Asunto(s)
Medicamentos Herbarios Chinos , Nefritis Lúpica , Humanos , Nefritis Lúpica/tratamiento farmacológico , Nefritis Lúpica/genética , Tripterygium , Simulación del Acoplamiento Molecular , Interferones , ARN Mensajero , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico
3.
BMC Complement Altern Med ; 16(1): 448, 2016 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-27825337

RESUMEN

BACKGROUND: Huang Lian Jie Du Decoction (HLJDD), a very famous traditional Chinese medicinal prescription, has been used for heat dissipation and detoxification in China. This study was aimed to evaluate the reno-protective effects of HLJDD against lupus nephritis (LN) in vivo in MRL/lpr mice. METHODS: Animals were administered orally every day for eight consecutive weeks except the mice of normal group and model group. Organ indexes, serum interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-gamma (IFN-γ) and the anti-double stranded DNA (anti-dsDNA) antibody were tested, respectively. Creatinine (Cr), blood urea nitrogen (BUN) and urine protein were measured for renal function evaluation. The expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT 3) in kidney tissue was observed by western blot (WB) and immunohistochemical (IHC) method. Meanwhile, histopathological changes in the renal were studied by hematoxylin-eosin (H&E) staining. RESULTS: The mice of HLJDD-treated group exhibited a significant reduced mortality (p < 0.05), serum anti-dsDNA level (p < 0.05) and renal immune complex deposition (p < 0.05), compared with the untreated MRL/lpr mice. In addition, HLJDD treatment remarkably reduced the levels of BUN, Cr, proteinuria (p < 0.01) and the levels of inflammatory cytokines such as IL-6, IL-10 and IFN-γ (p < 0.01). Moreover, HLJDD significantly suppressed the phosphorylations of STAT 3 (p < 0.05) and the renal pathological changes. CONCLUSIONS: The study implied that HLJDD may be a potential agent for the therapy of LN, and the down-regulated p-STAT 3 expression suggesting that it may be one of the LN therapy targets for HLJDD.


Asunto(s)
Medicamentos Herbarios Chinos/administración & dosificación , Nefritis Lúpica/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Femenino , Humanos , Interferón gamma , Interleucina-10/genética , Interleucina-10/inmunología , Interleucina-6/genética , Interleucina-6/inmunología , Riñón , Nefritis Lúpica/genética , Nefritis Lúpica/inmunología , Ratones , Ratones Endogámicos MRL lpr , Transducción de Señal
4.
PLoS One ; 9(6): e100255, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24945254

RESUMEN

Mortality from systemic lupus erythematosus (SLE), a prototypical autoimmune disease, correlates with the onset and severity of kidney glomerulonephritis. There are both preclinical and clinical evidence that SLE patients may benefit from consumption of n-3 polyunsaturated fatty acids (PUFA) found in fish oil, but the mechanisms remain unclear. Here we employed the NZBWF1 SLE mouse model to compare the effects of dietary lipids on the onset and severity of autoimmune glomerulonephritis after consuming: 1) n-3 PUFA-rich diet containing docosahexaenoic acid-enriched fish oil (DFO), 2) n-6 PUFA-rich Western-type diet containing corn oil (CRN) or 3) n-9 monounsaturated fatty acid (MUFA)-rich Mediterranean-type diet containing high oleic safflower oil (HOS). Elevated plasma autoantibodies, proteinuria and glomerulonephritis were evident in mice fed either the n-6 PUFA or n-9 MUFA diets, however, all three endpoints were markedly attenuated in mice that consumed the n-3 PUFA diet until 34 wk of age. A focused PCR array was used to relate these findings to the expression of 84 genes associated with CD4+ T cell function in the spleen and kidney both prior to and after the onset of the autoimmune nephritis. n-3 PUFA suppression of autoimmunity in NZBWF1 mice was found to co-occur with a generalized downregulation of CD4+ T cell-related genes in kidney and/or spleen at wk 34. These genes were associated with the inflammatory response, antigen presentation, T cell activation, B cell activation/differentiation and leukocyte recruitment. Quantitative RT-PCR of representative affected genes confirmed that n-3 PUFA consumption was associated with reduced expression of CD80, CTLA-4, IL-10, IL-18, CCL-5, CXCR3, IL-6, TNF-α and osteopontin mRNAs in kidney and/or spleens as compared to mice fed n-6 PUFA or n-9 MUFA diets. Remarkably, many of the genes identified in this study are currently under consideration as biomarkers and/or biotherapeutic targets for SLE and other autoimmune diseases.


Asunto(s)
Autoanticuerpos/biosíntesis , Linfocitos T CD4-Positivos/inmunología , Dieta , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-6/farmacología , Ácidos Grasos Insaturados/farmacología , Nefritis Lúpica/genética , Nefritis Lúpica/inmunología , Ácido Oléico/farmacología , Animales , Antígeno B7-1/genética , Antígeno B7-1/metabolismo , Linfocitos T CD4-Positivos/efectos de los fármacos , Antígeno CTLA-4/genética , Antígeno CTLA-4/metabolismo , Quimiocina CCL5/genética , Quimiocina CCL5/metabolismo , Citocinas/genética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Femenino , Aceites de Pescado/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Glomerulonefritis/inmunología , Glomerulonefritis/patología , Inmunoglobulina G/sangre , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Nefritis Lúpica/sangre , Ratones , Proteinuria/prevención & control , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores CXCR3/genética , Receptores CXCR3/metabolismo , Bazo/efectos de los fármacos , Bazo/metabolismo , Bazo/patología , Aumento de Peso/efectos de los fármacos
5.
Chin J Integr Med ; 17(4): 277-82, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21509671

RESUMEN

OBJECTIVE: To investigate the therapeutic effects and mechanisms of using artemisinin (Art) combined with glucocorticoid (GC) to treat lupus nephritis (LN) mice. METHODS: Forty hybrid female mice were randomly and equally divided into four groups with the method of random number table: control group, model group, prednisone group administrated with 6.45 mg/(kg·d) prednisone suspension, and Art+prednisone group administrated with 150 mg/(kg·d) Art suspension and 3.225 mg/(kg·d) prednisone suspension. A mice model of LN was established by injection with living lymph cell suspension. The changes of urine protein/24h, the expressions of GC receptor α (GRα) mRNA, GC receptor ß (GRß) mRNA in peripheral blood mononuclear cells (PBMCs), and transcriptional coactivator P300/CBP protein in renal tissue were measured. RESULTS: Compared with the model group, the treatment groups had significant decrease in urine protein/24 h, and renal pathological lesion (P<0.01). In the same groups, the expression of transcriptional coactivator P300/CBP protein in renal tissue and GRα mRNA were significantly increased, and GRß mRNA expression was significantly decreased (P<0.01). And the Art+prednisone group has a better therapeutic effect than the prednisone group (P<0.01). CONCLUSIONS: Art has therapeutic sensitization effects on GC in the LN mice. The underlying mechanism could be correlated with the effect of Art on the increase of the expressions of GRα mRNA and transcriptional coactivator P300 300/CBP protein in renal tissue and on the decrease of the expression of GRß mRNA in PBMC.


Asunto(s)
Artemisininas/farmacología , Modelos Animales de Enfermedad , Nefritis Lúpica/metabolismo , Prednisona/farmacología , ARN Mensajero/genética , Receptores de Glucocorticoides/genética , Factores de Transcripción p300-CBP/metabolismo , Animales , Artemisininas/administración & dosificación , Secuencia de Bases , Cartilla de ADN , Electroforesis en Gel de Agar , Femenino , Nefritis Lúpica/genética , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos DBA , Prednisona/administración & dosificación , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
6.
Front Biosci ; 13: 2900-8, 2008 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-17981762

RESUMEN

Over the past decade, accumulating evidence has indicated a crucial role for chemokines and chemokine receptors in the pathogenesis of autoimmune diseases in both human and mouse models. Locally secreted chemokines and their receptors are important mediators of leukocyte recruitment to the tissues, and contribute to the initiation and progression of autoimmune diseases. Thus, blockade of chemokine and chemokine receptor interactions has emerged as a novel therapeutic strategy. MRL/MpJ-lpr/lpr (MRL/lpr) and (NZB X NZW) F1 mice, the two strains of mice that develop spontaneous autoimmune disease closely resembling human systemic lupus erythematosus (SLE), are considered to be excellent models for investigating the pathogenesis of the human disease. In addition, similar expression patterns of chemokines and chemokine receptors in inflamed organs are shown in humans and lupus model mice, especially MRL/lpr mice. Therefore, findings obtained from experiments with lupus model mice may be applicable to the treatment of these autoimmune diseases in humans. In this article, we review the role of chemokines and chemokine receptors involved in the pathogenesis of autoimmune diseases and the therapeutic approach of chemokine blockade in lupus model mice.


Asunto(s)
Quimiocinas/metabolismo , Regulación de la Expresión Génica , Nefritis Lúpica/genética , Nefritis Lúpica/metabolismo , Animales , Artritis/metabolismo , Enfermedades Autoinmunes/metabolismo , Modelos Animales de Enfermedad , Humanos , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/metabolismo , Ratones , Ratones Endogámicos MRL lpr , Ratones Transgénicos , Receptores de Quimiocina , Sialadenitis/metabolismo
7.
Lupus ; 16(1): 18-24, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17283580

RESUMEN

Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Although treatment with corticosteroids and cytotoxic drugs may be useful in many cases, morbidity associated with these drugs and the relapsing nature of the disease make it necessary to develop new treatment strategies. Five-month old female NZB/W F1 mice were divided into the following groups: CYP group (n = 10), cyclophosphamide (CYP) 50 mg/kg intraperitoneally every 10 days; RAPA 1 group (n = 10) oral daily sirolimus (SRL), 1 mg/kg; RAPA 12 group (n = 13), oral daily SRL, 12mg/kg; FTY group (n = 10), oral fingolimod (FTY720), 2 mg/kg three times per week. An additional group of 13 non-treated mice were used as a control (control group). Follow-up was performed over four months. Animal survival, body weight, anti-DNA antibodies and proteinuria were determined. Kidneys were processed for conventional histology and immunofluorescence for IgG and complement. Total histological score (HS) was the sum of mesangial expansion, endocapillary proliferation glomerular deposits, extracapillary proliferation, interstitial infiltrates, tubular atrophy and interstitial fibrosis. All treated groups had lower proteinuria at the end of the follow-up with respect to the control group (P < 0.0001). Serum anti-DNA antibodies were appropriately controlled in RAPA 1 and CYP groups, but not in FTY or RAPA 12 groups. SRL and CYP arrested, and perhaps reversed almost all histological lesions. FTY720 ameliorated histological lesions but did not control mesangial expansion or interstitial infiltrates. SRL produces great improvement in murine lupus nephritis, while FTY720 seems a promising alternative if used in appropriate doses.


Asunto(s)
Inmunosupresores/uso terapéutico , Nefritis Lúpica/tratamiento farmacológico , Glicoles de Propileno/uso terapéutico , Sirolimus/uso terapéutico , Esfingosina/análogos & derivados , Administración Oral , Animales , Anticuerpos Antinucleares/sangre , Apoptosis/inmunología , Autoantígenos/inmunología , Movimiento Celular/efectos de los fármacos , Cromatina/inmunología , Complemento C3/análisis , Factor Nefrítico del Complemento 3/análisis , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Clorhidrato de Fingolimod , Mesangio Glomerular/patología , Inmunoglobulina G/análisis , Inmunosupresores/farmacología , Inyecciones Intraperitoneales , Glomérulos Renales/inmunología , Glomérulos Renales/patología , Nefritis Lúpica/genética , Nefritis Lúpica/inmunología , Nefritis Lúpica/patología , Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos NZB , Nucleosomas/inmunología , Glicoles de Propileno/administración & dosificación , Glicoles de Propileno/farmacología , Proteinuria/etiología , Receptores de Lisoesfingolípidos/efectos de los fármacos , Sirolimus/administración & dosificación , Sirolimus/farmacología , Esfingosina/administración & dosificación , Esfingosina/farmacología , Esfingosina/uso terapéutico
8.
Int Immunopharmacol ; 1(3): 551-9, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11367538

RESUMEN

Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan, HMG), a traditional Japanese herbal medicine, has been used for disorders accompanying aging. Oral administration of HMG from 8 to 16 weeks of age to MRL/lpr mice as a lupus-like autoimmune model ameliorated significantly some nephritis parameters, proteinuria and immune complex deposition in the kidney. Further, HMG reduced significantly the degree of lymphadenopathy and the serum level of immunoglobulin (Ig) G2a anti-dsDNA specific auto-antibody, even at 12 weeks of age. Simultaneously, interferon (IFN)-gamma production from anti-CD3 stimulated B220- T cells was suppressed by HMG, whereas interleukin (IL)-4 production was promoted. Examination of cytokine mRNA expressions in CD4 positive cells showed clearly that T cell differentiation was shifted from T helper (Th)1 to Th2 predominance by HMG. Furthermore, we demonstrated that HMG suppressed IL-12 mRNA expression in spleen cells which is a marker of Th1 predominance in MRL/lpr mice. These results suggested that HMG modulated an imbalance toward Th1 predominance in MRL/lpr mice through inhibition of IL-12 production and ameliorated autoimmune disorders.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Medicamentos Herbarios Chinos/farmacología , Células TH1/efectos de los fármacos , Células TH1/inmunología , Animales , Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/genética , Secuencia de Bases , Citocinas/biosíntesis , Citocinas/genética , Cartilla de ADN/genética , Femenino , Inmunoglobulina G/biosíntesis , Interleucina-12/genética , Japón , Nefritis Lúpica/tratamiento farmacológico , Nefritis Lúpica/genética , Nefritis Lúpica/inmunología , Enfermedades Linfáticas/tratamiento farmacológico , Enfermedades Linfáticas/genética , Enfermedades Linfáticas/inmunología , Ratones , Ratones Endogámicos MRL lpr , ARN Mensajero/genética , ARN Mensajero/metabolismo , Células Th2/efectos de los fármacos , Células Th2/inmunología
9.
Biochem Biophys Res Commun ; 200(2): 893-8, 1994 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-8179624

RESUMEN

Enrichment of diet with omega-3 lipid rich-menhaden fish oil (FO) when fed ad libitum to autoimmune lupus-prone NZB/NZW F1 (B/W) female mice delayed the onset and slowed progression of renal disease while significantly extending life-span compared to omega-6 lipid rich-corn oil (CO)-fed mice. Northern blot analysis of kidneys from FO-fed mice revealed no detectable levels of IL-1 beta, IL-6 and TNF alpha mRNA contrasted to levels that were easily detected in CO-fed mice. In contrast to the cytokines, FO-fed mice showed higher renal levels of the antioxidant enzymes-catalase, glutathione peroxidase (GSH-Px), superoxide dismutase (SOD)-mRNAs compared to CO-fed mice. The results suggest that dietary supplementation with FO, as compared to CO, inhibits the production of pro-inflammatory cytokines and ameliorates immune-complex-mediated kidney injury possibly by enhancing the ability of cells to dispose of harmful reactive oxygen intermediates.


Asunto(s)
Antioxidantes/metabolismo , Citocinas/metabolismo , Ácidos Grasos Omega-3/farmacología , Nefritis Lúpica/prevención & control , Animales , Catalasa/genética , Aceite de Maíz/farmacología , Femenino , Expresión Génica/efectos de los fármacos , Glutatión Peroxidasa/genética , Interleucina-1/genética , Interleucina-6/genética , Riñón/metabolismo , Nefritis Lúpica/dietoterapia , Nefritis Lúpica/genética , Ratones , Proteinuria/dietoterapia , Proteinuria/prevención & control , ARN Mensajero/genética , ARN Mensajero/metabolismo , Superóxido Dismutasa/genética , Factor de Necrosis Tumoral alfa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA